Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,166.51
-16.1100-1.36%
Post-market: 1,168.001.49+0.13%17:38 EDT
Volume:1.84M
Turnover:2.16B
Market Cap:1.10T
PE:39.16
High:1,193.30
Open:1,190.70
Low:1,158.41
Close:1,182.62
52wk High:1,292.65
52wk Low:783.85
Shares:945.38M
Float Shares:939.00M
Volume Ratio:0.91
T/O Rate:0.20%
Dividend:6.69
Dividend Rate:0.57%
EPS(TTM):29.79
EPS(LYR):22.95
ROE:102.29%
ROA:20.36%
PB:32.55
PE(LYR):50.83

Loading ...

Eli Lilly & Co. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
1 hour ago

Eli Lilly's Onswik Insulin Injection Wins UK Authorization for Type 2 Diabetes

MT Newswires Live
·
Yesterday

Walmart's List of Covered Medications Include Glp1s Like Novo's Ozempic and Lilly's Mounjaro, Alongside Some Insulin and Inhalers- Bloomberg News

THOMSON REUTERS
·
Yesterday

Missed Eli Lilly's Rally? Here Is What Holders Saw

Simply Wall St.
·
Yesterday

Sector Update: Healthcare Stocks Rise Late Afternoon

MT Newswires Live
·
Yesterday

Eli Lilly Likely to Post Strong Volume Growth in Q3, RBC Says

MT Newswires Live
·
Oct 12

Eli Lilly Price Target Maintained with a $1500.00/Share by RBC Capital

Dow Jones
·
Oct 12

Eli Lilly & Co (LLY) Receives a Buy from Barclays

TIPRANKS
·
Oct 12

Eli Lilly (LLY) Stock: Why Taking Profits Could Make Sense Ahead of 2027

TIPRANKS
·
Oct 11

Eli Lilly (LLY) Reported Broader Biomarker Effects In Phase 3b Psoriasis Trial

Simply Wall St.
·
Oct 11

The $3.8 Billion AI Startup With Zero Drugs — Why Big Pharma Keeps Signing the Checks

AI Industry Frontlines
·
Oct 11

1 Drugs Could Ease Back and Knee Pain, but Doctors Say There are Risks for Older Adults

Dow Jones
·
Oct 09

BofA Securities Adjusts Eli Lilly Price Target to $1,341 From $1,344, Maintains Buy Rating

MT Newswires Live
·
Oct 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 09

Eli Lilly announces new TOGETHER-PsO trial data

TIPRANKS
·
Oct 09

Lilly Says Phase 3b Together-PsO Data Show Broader Biomarker Shifts with Taltz Plus Zepbound vs Taltz Alone

Reuters
·
Oct 09

Eli Lilly price target lowered to $1,341 from $1,344 at BofA

TIPRANKS
·
Oct 09

Eli Lilly - Taltz and Zepbound Together Show Greater Reductions in Inflammatory Immune Activity

THOMSON REUTERS
·
Oct 09

Eli Lilly: Improvements were Maintained or Further Improved Through Week 52, with Safety Consistent with Known Profile of Each Respective Medicine

THOMSON REUTERS
·
Oct 09

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Advance Understanding of the Interconnected Immune and Metabolic Biology in Adults with Psoriasis and Obesity

THOMSON REUTERS
·
Oct 09